FRANKFURT, Jan 26 (Reuters) - Shares in German drugs and chemicals group Bayer (BAYG.DE: Quote, Profile, Research) fell more than 3 percent on Thursday after a study showed that its Trasylol drug doubled the risk of kidney failure. Analysts said the result of the study, in the New England Journal of Medicine, increased the risk for investors from Bayer’s pharmaceuticals business, which is recovering from a $1 billion recall of cholesterol drug Baycol over patient deaths.
